<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03552081</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/17/0344</org_study_id>
    <nct_id>NCT03552081</nct_id>
  </id_info>
  <brief_title>Tobacco and Sperm Genome: Effects of Smoking Cessation</brief_title>
  <acronym>TABAGERM</acronym>
  <official_title>Tobacco and Sperm Genome: Effects of Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tobacco is a male infertility risk factor. Many studies comparing smokers to non-smokers have
      shown effects on spermatogenesis and the quality of the male gamete. In vitro fertilization
      success rates are decreased in smokers and in natural procreation the time required to
      conceive (excellent fertility indicator) seems to be lengthened in the smoker. The
      prospective study that the investigators propose to carry out would make it possible to know
      the time required for the repair of the sperm abnormalities and in particular the DNA of the
      gametes generated by the smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tobacco is a male infertility risk factor. Many studies comparing smokers to non-smokers have
      shown effects on spermatogenesis and the quality of the male gamete. In vitro fertilization
      success rates are decreased in smokers and in natural procreation the time required to
      conceive (excellent fertility indicator) seems to be lengthened in the smoker. Tobacco is a
      well-known mutagen. It will induce damage to the male gametes DNA. Tobacco increases the
      oxydation of DNA. Exposure to tobacco increases the percentage of spermatozoa with broken DNA
      or defective chromatin and induces gametes aneuploidy as has been reported in several
      studies. The set of effects of tobacco on the male gametes questions the consequences for the
      conceptus (from embryo to adult). The prospective study that the investigators propose to
      carry out would make it possible to know the time required for the repair of the sperm
      abnormalities and in particular the DNA of the gametes generated by the smoking. Indeed, a
      cycle of spermatogenesis extending over 74 days, it would be important to know if it is
      necessary to wait a complete cycle or even more before proposing a management. It would
      therefore be possible to find the most favorable period for reducing tobacco-related risks
      and for effective management.

      A blood test will be performed at T0 (before weaning) and during follow-up at 3, 6 and 12
      months for the determination of the Inhibin hormones and testosterone. Sperm analysis at the
      different follow-up times will be carried out at CECOS using a standardized methodology
      (WHO). Two tests of analysis will be used in this study on each sample: the TUNEL test and
      the SCSA. A measurement of DNA oxidation will also be performed, as well as a study of
      spermatic aneuploidy (in situ hybridization technique of fluorescent centromeric chromosomal
      probes).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the Percentage of spermatozoa presenting a fragmented DNA from Baseline to 12 months after smoking cessation</measure>
    <time_frame>Up to 12 months after smoking cessation</time_frame>
    <description>TUNEL technique will be performed to evaluate the percentage of spermatozoa presenting a fragmented DNA at day 0 (before weaning = baseline), and 12 months after smoking cessation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the Percentage of spermatozoa presenting a fragmented DNA from Baseline to 3 months after smoking cessation</measure>
    <time_frame>Up to 3 months after smoking cessation</time_frame>
    <description>TUNEL technique will be performed to evaluate the percentage of spermatozoa presenting a fragmented DNA at day 0 (before weaning = baseline), and 3 months after smoking cessation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the Percentage of spermatozoa presenting a fragmented DNA from Baseline to 6 months after smoking cessation</measure>
    <time_frame>Up to 6 months after smoking cessation</time_frame>
    <description>TUNEL technique will be performed to evaluate the percentage of spermatozoa presenting a fragmented DNA at day 0 (before weaning = baseline), and 6 months after smoking cessation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of 8-OHdG gamete DNA</measure>
    <time_frame>Up to 12 months after smoking cessation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spermogram exam</measure>
    <time_frame>Up to 12 months after smoking cessation</time_frame>
    <description>Spermogram examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fragmentation index (DFI) of gamete DNA</measure>
    <time_frame>Up to 12 months after smoking cessation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneuploid sperm count</measure>
    <time_frame>Up to 12 months after smoking cessation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>luteinizing hormone (LH) levels luteinizing hormone (LH) levels luteinizing hormone (LH) levels</measure>
    <time_frame>Up to 12 months after smoking cessation</time_frame>
    <description>Blood samples at day 0 (before weaning), and at 3 months, 6 months, 12 months after smoking cessation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone levels</measure>
    <time_frame>Up to 12 months after smoking cessation</time_frame>
    <description>Blood samples at day 0 (before weaning), and at 3 months, 6 months, 12 months after smoking cessation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Male Infertility</condition>
  <arm_group>
    <arm_group_label>fragmented DNA evaluation in blood and semen samples</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 men followed for smoking cessation will be included in the study in order to evaluate the time required for the repair of the sperm abnormalities and in particular the DNA of the gametes generated by the smoking</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fragmented DNA evaluation in blood and semen samples</intervention_name>
    <description>The objective will be to evaluate the decrease in the percentage of sperm with spermatic DNA fragmentation by the TUNEL technique following the evolution of this rate to 3 months, 6 months and 12 months after cessation of smoking by blood and semen samples.</description>
    <arm_group_label>fragmented DNA evaluation in blood and semen samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1st Consultation in the Tobacco Control Co-ordination Unit,

          -  Affiliate or beneficiary of a social security scheme

          -  Free, informed and written consent signed by the participant and the investigator

        Exclusion Criteria:

          -  febrile state during the 3 months before inclusion,

          -  antecedent consultation for male infertility,

          -  BMI&gt; 30,

          -  Medical and / or surgical history that can alter spermatogenesis -Chemotherapy /
             Radiation Therapy / IRA-therapy, Cryptorchidism, testicular Torsion, significant
             varicocele, chronic, progressive disease,

          -  hypovolemia &lt;1.6ml

          -  Major persons protected by law (guardianship, curators, safeguarding of justice)

          -  Patients in periods of exclusion for another clinical research protocol

          -  Co-addiction (cannabis, alcohol, other drugs)

          -  Neuropsychiatric Pathology, considered serious by the investigator

          -  Psychotropic treatment (antidepressant, anxiolytic, antipsychotic)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Moreau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Moreau, MD</last_name>
    <phone>05 67 77 10 17</phone>
    <email>moreau.j@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Toulouse, Service de m√©decine de la reproduction</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Moreau, MD</last_name>
      <email>moreau.j@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jessica Moreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spermatogenesis</keyword>
  <keyword>tobacco</keyword>
  <keyword>DNA Fragmentation Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

